| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.0092 | 0.7 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |